Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration‐resistant prostate cancer patients

Docetaxel plus prednisone is currently the standard first‐line treatment in metastatic castration‐resistant prostate cancer (mCRPC). The aim of this study was to assess the clinical activity and pharmacodynamic/pharmacogenetic profile of docetaxel plus prednisone in combination with metronomic cyclophosphamide in mCRPC patients.

[1]  R. Gomis,et al.  Cyclooxygenase‐2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice , 2014, BJU international.

[2]  M. Picardo,et al.  Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. , 2013, Future oncology.

[3]  G. Francia,et al.  VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide , 2013, British Journal of Cancer.

[4]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[5]  S. Olgac,et al.  Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer. , 2013, The oncologist.

[6]  M. Gleave,et al.  Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Yu,et al.  Castrate-resistant prostate cancer: postdocetaxel management , 2013, Current opinion in urology.

[8]  P. Paliwal,et al.  Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel , 2013, Cancer management and research.

[9]  N. Clarke.  Landmarks in non‐hormonal pharmacological therapies for castration‐resistant prostate cancer , 2012, BJU international.

[10]  J. Burke,et al.  Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  H. Mackay,et al.  Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis , 2012, Clinical Cancer Research.

[12]  P. Kantoff,et al.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Bocci,et al.  Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? , 2012, Critical reviews in oncology/hematology.

[14]  T. Nelius,et al.  Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. , 2011, Cancer treatment reviews.

[15]  P. Albers,et al.  Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Danesi,et al.  Metronomic Chemotherapy for Metastatic Prostate Cancer , 2010, Drugs & aging.

[17]  L. Landi,et al.  METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION‐RESISTANT PROSTATE CANCER , 2010, Journal of the American Geriatrics Society.

[18]  S. Steinberg,et al.  Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Goldhirsch,et al.  Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab , 2009, Clinical Cancer Research.

[20]  D. Venzon,et al.  The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors , 2009, Molecular Cancer Therapeutics.

[21]  L. Landi,et al.  Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer , 2009, Clinical Cancer Research.

[22]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[23]  S. Solomon,et al.  Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis , 2008, Circulation.

[24]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Pfister,et al.  Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer , 2007, BJU international.

[26]  R. Kerbel,et al.  Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice , 2007, Molecular Cancer Therapeutics.

[27]  M. Gross,et al.  A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer , 2007, BMC cancer.

[28]  C. Tangen,et al.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.

[29]  S. Steinberg,et al.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  R. Kerbel,et al.  Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. , 2005, Cancer research.

[31]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[32]  C. Cordon-Cardo,et al.  Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism , 2005, Clinical Cancer Research.

[33]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Maltezos,et al.  VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. , 2004, Lung cancer.

[35]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[36]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Pruthi,et al.  A pilot study of use of the cyclooxygenase‐2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy , 2004, BJU international.

[38]  W. Oh,et al.  A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma , 2003, Cancer.

[39]  A. Barqawi,et al.  Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma , 2003, Cancer.

[40]  R. Kerbel,et al.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[42]  M. Egorin,et al.  Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  B. Teicher,et al.  An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. , 2002, Cancer research.

[44]  Peter Bohlen,et al.  Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. , 2002, Cancer research.

[45]  R. Kerbel,et al.  A role for survivin in chemoresistance of endothelial cells mediated by VEGF , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Masferrer,et al.  Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.

[47]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Danesi,et al.  Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. , 2007, Pharmacogenomics.

[49]  P. Carmeliet,et al.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.